Alembic Pharmaceuticals Q1 Results FY26: Q1 PAT Soars 14.60% to ₹154.38 Crore; Revenue Up 9.54% YoY
Posted by : sachet | Tue Aug 05 2025
Alembic Pharmaceuticals Q1 Results FY26: Alembic Pharmaceuticals posted its Q1 results on 5th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹154.38 crores against revenue of ₹1,710.72 crores. During Q1 FY26, the profit increase of the company was recorded at 14.60% YoY, and the revenue increase for the same period was 9.54%.
Alembic Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹1,710.72 | ₹1,561.73 |
| Profit Before Tax (PBT) | ₹287.84 | ₹238.93 |
| Profit After Tax (PAT) | ₹154.38 | ₹134.71 |
(Figures in crores)
Alembic Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹1,494.17 | ₹1,475.56 |
| Profit Before Tax (PBT) | ₹221.53 | ₹294.57 |
| Profit After Tax (PAT) | ₹103.52 | ₹176.19 |
(Figures in crores)
Alembic Pharmaceuticals Q1 Results FY26 Highlights (Q1 FY26 vs FY25)
- Alembic Pharmaceuticals clocked Q1 FY26 consolidated revenue of ₹1,710.72 crores vs ₹1,561.73 crores.
- On the profit front, Alembic Pharmaceuticals earned a consolidated PAT of ₹154.38 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹134.71 crore.
- Consolidated PAT rose for the first quarter of FY26, was 14.60% YoY, and revenue rose 9.54% YoY.
- As per the standalone figures, the quarterly PAT of Alembic Pharmaceuticals has decreased by 41.25% and revenue has increased by 1.26% YoY.
Alembic Pharmaceuticals Share Price Performance
On the opening bell of 5th August 2025, the shares of Alembic Pharmaceuticals opened at ₹980.00 per share. However, the initial gains are wiped out as of now, and Alembic Pharmaceuticals shares are trading at ₹946.00 per share, lower than their opening price.
Considering the long-term performance, Alembic Pharmaceuticals shares have yielded close to -20.92% returns in the past 1 year, and 5-year returns stand at -10.00%. Over the maximum timeframe, the Alembic Pharmaceuticals share provided 1,934.41% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Alembic Pharmaceuticals shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Also Read : NTPC Green Energy Q1 Results FY26: Q1 PAT Rose 59.07% to ₹220.48 Crore; Revenue Surged 17.59% YoY
Recent Articles
Marico Q1 Results FY26: Q1 PAT Up 8.62% to ₹504.00 Crore; Revenue Surged 23.31% YoY
Shree Cement Q1 Results FY26: Q1 PAT Surges 130.67% to ₹642.66 Crore; Revenue Surged 3.06% YoY
Escorts Kubota Q1 Results FY26: Q1 PAT Jumps 363.16% to ₹1,397.11 Crore; Revenue Down 2.86% YoY
Knowledge Realty Trust REIT IPO GMP & Review: Apply or Avoid?
BLT Logistics IPO GMP & Review: Apply or Avoid?
RR Kabel Q1 Results FY26: Q1 PAT Jumps 39.44% to ₹89.77 Crore; Revenue Surged 13.85% YoY
Kirlosker Brothers Q1 Results FY26: Q1 PAT Soars 2.46% to ₹66.70 Crore; Revenue Declined 5.03% YoY
Aaradhya Disposal IPO GMP & Review: Apply or Avoid?
Aarti Industries Q1 Results FY26: Q1 PAT Down 68.61% to ₹43.00 Crore; Revenue Declined 9.45% YoY
